Sign in
Taking people in United StatesNo phase

Home device to monitor swelling in people with heart failure

Tests a home device that tracks leg swelling in adults with chronic heart failure.

Key facts

Who runs it
Heartfelt Technologies
Where
Bala-Cynwyd, Hackensack, and Little Rock, United StatesSee the 3 sites
Trial code
Registry title
The HEARTFELT Study
Status
Recruiting
People taking part
1,500 people, planned
Started
23 Oct 2025
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Heartfelt Device installed
  • Standard care
  • Heartfelt-guided care
  • Questionnaires
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 22 or older with long-standing heart failure and leg swelling who often miss their home monitoring. They take daily water tablets (diuretics) and are at risk of hospital stays.

Age
22 years or older, no upper age limit.
Sex
Men and women can join.
Disease stage
Chronic heart failure diagnosed at least 2 months before the trial starts, with a past record of swelling in the feet and lower legs. They must also have had a recent heart failure hospital stay, urgent visit or injected diuretic treatment, or be judged by a clinician at high risk of a hospital stay in the next 6-12 months.
Earlier treatment
The trial is looking for people who take diuretics every day. They must also not follow their home monitoring or treatment plan well, for example by recording less than 50% of the expected days of data over 180 days.

Main reasons for not taking part

  • Bandages on the lower legs every day
  • Both feet amputated, wheelchair use at home, or bed-bound
  • Regular dialysis
  • Two or more leg blood clots (DVT) or leg skin infections (cellulitis) in the last 12 months
  • Pregnant, or able to have children and not using medically approved birth control

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form (wet or digital signature)
  • Male or female, aged 22 to [No maximum age]
  • Diagnosed with Chronic Heart failure at least 2 months prior to randomization
  • Documented history of peripheral edema (edema in feet and lower legs), defined as at least one clinical mention in the medical record indicative of oedema during prior clinical assessment
  • Evidence of heart failure decompensation or elevated risk of future hospitalization, defined by one or more of the following:; Hospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR; Receipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR; Emergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR; Clinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden)
  • Patients who are treated with daily diuretics
  • Evidence of non-adherence defined by one or more of the following:; Participants with ≥180 days of historical monitoring/device data available; Failure to collect ≥50% of expected days of prescribed home physiological monitoring data (e.g. weight, blood pressure, or other clinician-recommended measurements), assessed over a continuous 180-day period; OR; Discontinuation from a remote patient monitoring/home monitoring program due to non-adherence; OR; Failure to adhere to a prescribed home-based therapy/monitoring intervention, supported by device usage data showing <50% of expected days of use over a continuous 180-day period; Participants without ≥180 days of historical monitoring/device data available: Evidence of non-adherence may be demonstrated by low data capture over shorter windows, defined as any of the following :; ≤2 days of monitoring data recorded for each of the most recent 4 consecutive weeks during which any remote monitoring device was continuously available in the patient's home; OR; ≤3 days of monitoring data recorded in any consecutive 8 week period period during which any remote monitoring device was continuously available in the patient home; AND/OR; by documented non-adherence in the medical record within the last 3 years:; Historical documentation of persistent medication and/or dietary non-adherence, defined as either a clear statement of ongoing non-adherence or ≥2 documented instances of non-adherence concerns (including dosing and/or timing, where available); OR; Historical documentation on repeated clinical assessments indicating persistent difficulty adhering to recommended self-management activities (e.g. repeated failure to follow monitoring instructions, incomplete engagement with care plan, or repeated non-attendance at scheduled reviews); For participants not previously enrolled in RPM or without sufficient historical monitoring data, non-adherence will be assessed prospectively using connected scales provided at study initiation. Objective adherence metrics derived from scale usage during the initial monitoring period will be used both to characterise baseline adherence and to support predefined subgroup analyses; Clinical teams/PIs discretion as patients being non-adherent
  • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of the study
  • Patients who are covered by an insurance plan that covers IDE-B costs (e.g. Medicare Part-B), OR written contract signed by the patient, or their provider or payor, stating that they will be liable for any trial-associated costs that Medicare would ordinarily cover if the patient were covered by Medicare

Who cannot take part

  • Participant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months)
  • Participant has a history of recurrent leg or feet cellulitis episodes (two or more episodes within the last 12 months)
  • Participant has bandages to lower limbs every day
  • Participant has an amputation of both feet
  • Participant is a regular wheelchair user inside their home
  • Participant is bed-bound
  • Participant is of no fixed abode
  • Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes
  • Participant is unable to take diuretics
  • Participant is on a regular schedule of dialysis
  • Participant is prescribed diltiazem or verapamil on an ongoing basis
  • Participant is pregnant or is not taking medically approved birth control if of child-bearing potential

Where in United States

  • Connect AmericaBala-Cynwyd, United StatesContact: Rosemary Kennedy, PhD,RN,FAANTaking people
  • HealthArcHackensack, United StatesContact: Kaitlyn Batch-Monteforte, BSN., RN.Taking people
  • Baptist HealthLittle Rock, United StatesContact: WH Wilson Tang, MDNo longer taking part

About the trial

What the trial wants to find out

This pragmatic randomized crossover trial looks at the effect(s) of using a remote patient monitoring device (Heartfelt device) with health alerts to monitor the development of peripheral edema in patients with heart failure (HF). The hypothesis is that this passive measurement method will lead to better data availability, which in turn will improve patient care and reduce hospitalizations for the management of worsening HF (HF hospitalizations, HFHs) in nonadherent participants with chronic HF. The study objectives are:

Read full original descriptionShow less

* Primary objective: Establish if the Heartfelt device is safe to use and effective at reducing HFHs. * Secondary objectives:

1. Establish the effect of the Heartfelt device on data availability compared to existing remote monitoring devices. 2. Establish the effect of the Heartfelt device on HF clinical outcomes.

Participants will need to:

* Install the device in their home for at least a year and up to 4 additional years after. * Reply to remote patient monitoring phone calls to follow the care plans.

The 2 groups in the trial

  • Standard Care (control)Existing treatment, for comparison

    Device is installed and data is captured but volume measurements and health alerts are not transmitted to the RPMP.

    Treatment: Heartfelt Device installed, Standard care, and Questionnaires

  • Standard Care + Heartfelt (intervention)Treatment being tested

    Device is installed and data is captured, and volume measurements and health alerts are transmitted to the RPMP for review and potential follow-up (per a pre-specified alert protocol).

    Treatment: Heartfelt Device installed, Standard care, Heartfelt-guided care, and Questionnaires

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Pragmatic, Single-blind, Randomized Crossover Trial Testing the Effectiveness of Autonomous Remote Patient Peripheral Edema Monitoring and Reporting in HEART FailurE Compared to conventionaL remoTe Patient Monitoring.
Plain-language title
Home device to monitor swelling in people with heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 October 2026